SEC 13F最新季度 2026 Q3·持仓截至 2026-09-30·距今约 1.6 个月 (50 天)
2026 Q3 已收录 30 / 33 家 (3 家未收到)
MRNA生命科学与高端医疗● 实时行情已联动

Moderna, Inc.

当前追踪的 33 家顶级对冲基金 2026 Q3 13F 申报中暂无重仓该标的记录

实时市价
今日涨跌
重仓顶级机构数
0/ 33 家

渗透率: 0.0%

平均持仓占比
0%

-

本季净增持机构占比
0%净增持/建仓
+0/0/-0

💡 口径说明:变动幅度超过 ±0.5% 计为加仓增持/减仓减持,±0.5% 以内计为持仓不变;净增持占比 = (增持家数 + 新建仓家数) / 持仓机构总数。

机构总持股量
0股

基于 2026 Q3 SEC 13F 申报

SGDC Dual-Core Engine超级成长股双核驱动模型

🚀MRNA SGDC 量化评级与战术档案

打开 SGDC 选股器↗
4P 综合质地
C 级(61分)
RS 相对强度
75/ 99
技术形态 / 状态
形态蓄势
基部枢纽参考价
$280.80破位防守 暂无支撑

📌 核心业务与护城河简评:Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

ℹ️
13F × SGDC 共振状态:未进入当季共振池动量分: 68.0动量结算: 2026-11-18 收盘

截至 2026-11-18 收盘,股价处于 50SMA 均线下方修正期(收盘结算价 $196.79 < 50SMA $205.61),触发动量风控拦截。

查看当季 2 只双共振龙头→
ℹ️
华尔街 13F 机构持仓覆盖说明本站当前重点追踪的全球 33 家顶级百亿对冲基金(如巴菲特伯克希尔、达利欧桥水、西蒙斯文艺复兴、肯·格里芬城堡等)最新季度 SEC 13F 申报中暂无 MRNA 的重仓数据。✦ 提示:该标的已通过 SGDC 超级成长股双核模型严格筛选(4P 质地评级 C 级,RS 相对强度 75)。

📈近 8 个季度机构持股演变趋势

追踪该标的在过去 8 个季度中被全球顶尖百亿基金持有数量与平均权重的历史变迁

切换季度查看明细:
0% 均仓
0 家2026 Q3
0% 均仓
0 家2026 Q2
0% 均仓
0 家2026 Q1
0% 均仓
0 家2025 Q4
0% 均仓
0 家2025 Q3
0% 均仓
0 家2025 Q2
0% 均仓
0 家2025 Q1
0% 均仓
0 家2024 Q4
0% 均仓
0 家2024 Q3
2026 Q3|报告期基准日: 2026-09-30
重仓机构: 0 家合计持股: 0平均仓位: 0%

🏛️持有该股的顶级机构明细2026 Q3

查看 2026 Q3 重仓该股的每家对冲基金经理、持股数量、仓位权重与调仓动向

排序:
投资大佬 / 机构基金管理规模持仓权重持有股数季度动向操作
当前暂无顶级对冲基金持有该标的
🎯

想知道华尔街大佬们本期最抱团的前 50 只暗牌金股?

与其单只股票反查,不如直接在共识筛股器中获取 33 家对冲基金共同重仓的 Alpha 清单。

前往共识筛股器查看全量名单 →

⚡准备建仓或研究 MRNA?

将该标的添加至您的独立交易日记或股息追踪系统,系统将自动关联华尔街机构持仓成本变动。